Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07459543CT.gov A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India | — | Not Yet Recruiting | — | — | — |
NCT06319196CT.gov Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | — | Recruiting | — | — | — |
NCT07504796CT.gov ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | — | Recruiting | — | — | — |
NCT07223411CT.gov Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | — | Recruiting | — | — | — |
NCT06712927CT.gov Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | — | Recruiting | — | — | — |
NCT06624644CT.gov A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | — | Recruiting | — | — | — |
NCT07091695CT.gov Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | — | Completed | — | — | — |
NCT06683755CT.gov Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | — | Not Yet Recruiting | — | — | — |
NCT07079644CT.gov Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database | — | Completed | — | — | — |
NCT05629546CT.gov Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | — | Recruiting | — | — | — |
Show 16 more trialsShow fewer
NCT06246916CT.gov A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | — | Recruiting | — | — | — |
NCT06264180CT.gov VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | — | Recruiting | — | — | — |
NCT06112314CT.gov IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | — | Recruiting | — | — | — |
NCT06295159CT.gov Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | — | Recruiting | — | — | — |
NCT06101134CT.gov A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | — | Active Not Recruiting | — | — | — |
NCT05970497CT.gov A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05418972CT.gov A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma | — | Active Not Recruiting | — | — | — |
NCT05912244CT.gov A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma | — | Active Not Recruiting | — | — | — |
NCT05625399CT.gov A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | — | Active Not Recruiting | — | — | — |
NCT05428007CT.gov Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | — | Recruiting | — | — | — |
NCT03978611CT.gov A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | — | Terminated | — | — | — |
NCT05002569CT.gov A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT03743766CT.gov Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | — | Completed | — | — | — |
NCT03724968CT.gov Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | — | Terminated | — | — | — |
NCT03470922CT.gov A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | — | Active Not Recruiting | — | — | — |
NCT02465060CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Relatlimab (this asset) | Bristol-Myers Squibb | Approved | B · 63 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Relatlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | BB · 68 |
| Cutaneous Melanoma | — | P3 | BB · 66 |
| Metastatic Melanoma | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Relatlimab in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/relatlimab-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →